PAVmed Inc. reports recurring business updates as a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Company updates commonly address financial results, capital-structure actions, medical device portfolio development and subsidiary activity.
News also covers Lucid Diagnostics, PAVmed's commercial-stage cancer prevention diagnostics subsidiary, including EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device activity for patients at risk of esophageal precancer and cancer. Other recurring subjects include Veris Health digital health programs, the Veris Cancer Care Platform, implantable physiological monitor development and PAVmed's endoscopic esophageal imaging technology through Octeris.
Lucid Diagnostics (LUCD) has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test and closed a preferred-stock financing. Payments on claims for tests performed at one of its two CLIA-certified laboratories are being received at the established rate of $1,938.01 per test.
The $15.0 million private placement closed October 21, 2026, with existing long-term shareholders. Series C Convertible Preferred Stock was sold for $1,000 per share and converts into common stock at $0.3519 per share. Lucid intends to use net proceeds to accelerate near-term commercial operations and for working capital and general corporate purposes. Participating noteholders acknowledged that Medicare payments addressed concerns underlying the notes' Medicare-related default provision.
Lucid Diagnostics (LUCD) reported progress on multiple payment, billing, and coding pathways for its EsoGuard esophageal DNA test and EsoCheck cell collection device following three U.S. healthcare policy meetings in mid-September 2026.
A Medicare Advisory Panel recommended maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule, with final CMS determinations expected in November after public comment. The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection procedures performed with EsoCheck. In addition, the ICD-10 Coordination and Maintenance Committee received a Lucid-backed proposal for diagnosis code R85.83 to report positive EsoGuard results, which the committee received positively and may finalize after comments.
Lucid plans to begin submitting Medicare claims under PLA code 0114U from its Texas laboratory this month and from its California laboratory once a revised Local Coverage Determination becomes effective.
PAVmed (NASDAQ: PAVM) reported a second-quarter 2026 business update covering its subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health and Octeris Medical, along with financial results for the quarter ended June 30, 2026.
Veris increased patient onboarding as its commercial engagement with OSU-The James advanced and continued development of its implantable physiological monitor toward a planned early 2027 FDA 510(k) submission. Lucid recognized $1.5 million in EsoGuard revenue on 2,770 tests, secured its first laboratory benefit manager coverage policy deeming EsoGuard medically necessary for eligible patients, and developed a cost-effectiveness model to support payor discussions.
PAVmed highlighted PortIO first-in-human data showing 100% device patency, 90% completion of intended implant duration and no device-related adverse events, and ongoing FDA pre-submission work. Octeris advanced its multimodal endoscopic imaging probe toward clinical validation. For Q2 2026, PAVmed reported revenue of $33,000, operating expenses of $7.1 million, GAAP net loss attributable to common stockholders of approximately $5.5 million (or $(0.87) per diluted share), non-GAAP adjusted loss of $1.7 million, and cash of $3.8 million as of June 30, 2026.
Lucid Diagnostics (Nasdaq: LUCD) reported second quarter 2026 EsoGuard revenue of $1.474 million, up from $1.163 million in 2Q25, and processed 2,770 EsoGuard Esophageal DNA Tests. The company highlighted strengthening commercial activity, including its first laboratory benefit manager coverage policy via Concert, now part of Lyric, adopted by multiple client health plans.
For the quarter ended June 30, 2026, Lucid recorded operating expenses of $14.3 million and a GAAP net loss of $11.7 million, with net loss attributable to common stockholders of $14.7 million, or $(0.08) per share. Non-GAAP adjusted loss was $10.9 million, or $(0.06) per share. Lucid held $33.4 million in cash and cash equivalents at June 30, 2026, compared with $34.7 million at December 31, 2025, and reported EBITDA of $(11.5) million. The company also developed a health economic cost-effectiveness model to support payor engagement for EsoGuard.
Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer.
The policy cites sufficient evidence in guidelines and peer-reviewed literature to demonstrate improved health outcomes and deems Lucid’s EsoGuard Esophageal DNA Test medically necessary for patients who meet American College of Gastroenterology (ACG) screening criteria. According to Lucid, multiple Concert client health plans have already adopted this policy, supporting broader commercial access to EsoGuard and reinforcing the company’s clinical evidence base.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will participate in two investor events: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026 and the Canaccord Genuity 46th Annual Growth Conference fireside chat on August 11, 2026 at 11:30 AM ET in Boston, MA. The Canaccord fireside chat will be available via live and archived webcast through the Investor Relations section of the Lucid Diagnostics website, with a replay accessible for 30 days after the live broadcast.
PAVmed (Nasdaq: PAVM) announced it will host a second quarter 2026 business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss business operations and growth strategy, and President/CFO Dennis McGrath will review second quarter 2026 financial results.
Lucid Diagnostics (Nasdaq: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), will host a second quarter 2026 business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. Management will review business operations, growth strategy, and second quarter 2026 financial results. The live webcast and a 30-day replay will be available in the investor relations section of luciddx.com, with telephone access for U.S. and international callers.
PAVmed (NASDAQ:PAVM) reported Q1 2026 results and a business update spanning Lucid Diagnostics (NASDAQ:LUCD) and Veris Health. Revenue was $22 thousand, operating expenses $8.1 million, and GAAP net loss attributable to common stockholders about $7.0 million or $(4.42) per share. Non-GAAP adjusted net loss was $1.9 million or $(1.17) per share. Cash and equivalents rose to $6.5 million from $1.5 million at year-end. Lucid recognized $1.3 million in EsoGuard revenue on 3,177 tests and raised roughly $17 million, ending with $45 million pro forma cash and runway into 2027. Veris advanced its implantable physiological monitor toward a planned FDA 510(k) submission and expanded its commercial engagement with OSU-The James.
Lucid Diagnostics (Nasdaq: LUCD) reported first quarter 2026 results and a business update. The company processed 3,177 EsoGuard tests and generated $1.256 million in revenue, with operating expenses of $13.4 million and GAAP net loss of $13.9 million, or $(0.17) per share.
Non-GAAP adjusted loss was $10.5 million. An underwritten equity offering added about $17 million, supporting $45 million in proforma cash and runway into 2027. Management highlighted efforts toward Medicare coverage, expanded payer and health system engagement, and a strong presence at DDW with EsoGuard clinical data and guideline visibility.